Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sets New 1-Year Low – What’s Next?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) reached a new 52-week low during trading on Monday . The company traded as low as $26.59 and last traded at $26.68, with a volume of 29974 shares. The stock had previously closed at $27.05.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LKFT shares. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday, February 26th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research cut shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares has an average rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Price Performance

The business’s 50-day moving average price is $29.73 and its two-hundred day moving average price is $31.63. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -18.99 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. As a group, sell-side analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently modified their holdings of the company. State of Wyoming acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $28,000. Van ECK Associates Corp raised its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 750 shares during the last quarter. Arax Advisory Partners raised its position in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,778 shares during the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $134,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $211,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.